Acitretin Therapy Guidelines for Adult Psoriasis

Dosing and Administration

• Initiate therapy with 25–30 mg oral acitretin once daily taken with food or milk for 2–4 weeks to optimize absorption and tolerability. (Guideline recommendation) 1
• Employ gradual dose escalation after the initial period, adjusting to a maintenance dose of 25–50 mg daily for an additional 6–8 weeks to achieve optimal therapeutic response. (Guideline recommendation) 1
• Maximum dose of 75 mg daily may be required in refractory cases, but higher doses increase mucocutaneous side‑effects. (Guideline recommendation) 1
• Lower doses (≤25 mg/day) are preferred when acitretin is combined with phototherapy to minimize adverse effects. (Guideline recommendation) 2
• Clinical response is gradual, typically requiring 3–6 months to reach peak efficacy; set expectations accordingly. (Guideline recommendation) 1

Baseline Assessment

• Perform a comprehensive history and physical examination before starting therapy. (Guideline recommendation) 2
• Obtain baseline fasting lipid profile (cholesterol and triglycerides). (Guideline recommendation) 1
• Obtain baseline complete blood count (CBC). (Guideline recommendation) 2
• Obtain baseline liver function tests (LFTs). (Guideline recommendation) 3
• Assess renal function (e.g., serum creatinine, eGFR). (Guideline recommendation) 4
• Perform a pregnancy test in women of child‑bearing potential. (Guideline recommendation) 2

Ongoing Monitoring

Intensive Phase (first 2 months)

• Check LFTs and lipid profile every 2–4 weeks; if abnormalities arise, increase monitoring to weekly and adjust dose as needed. (Guideline recommendation) 1

Maintenance Phase (after 2 months)

• LFTs and lipid profile every 3 months. (Guideline recommendation) 1, 2, 3
• CBC and renal function every 3 months. (Guideline recommendation) 2, 3
• Pregnancy testing every 3 months when indicated. (Guideline recommendation) 2, 3

Special Considerations for Diabetic Patients

• Monitor blood glucose at the same intervals as LFTs/lipids. (Guideline recommendation) 1
• Advise more frequent capillary glucose checks during the first few weeks of treatment. (Guideline recommendation) 1

Safety Management

Hepatotoxicity

• Discontinue acitretin if transaminases rise to > 3 × upper limit of normal. (Guideline recommendation) 1
• Refer to gastroenterology if bilirubin exceeds 50 µmol/L or ALT exceeds 200 IU/L. (Guideline recommendation) 1
• Continue hepatic monitoring for ≥ 3 months after discontinuation. (Guideline recommendation) 1

Lipid Abnormalities

• Triglycerides > 5 mmol/L – refer to a lipid specialist and evaluate secondary causes (e.g., alcohol, diabetes, hypothyroidism). (Guideline recommendation) 1
• Triglycerides ≥ 10 mmol/L – immediately discontinue acitretin and arrange urgent lipidology referral due to pancreatitis risk. (Guideline recommendation) 1
• If therapeutic response is satisfactory but lipids remain elevated, initiate dietary modifications before adding lipid‑lowering agents. (Guideline recommendation) 1

Contraindications

• Pregnancy – teratogenic; multiple malformations especially when exposure occurs between weeks 3–6 of gestation. (Guideline recommendation) 5
• Women of child‑bearing potential must use effective contraception for 3 years after stopping acitretin (to cover possible conversion to etretinate). (Guideline recommendation) 1
• Severe hepatic or renal impairment – contraindicated. (Guideline recommendation) 2
• Chronically elevated blood lipids – contraindicated. (Guideline recommendation) 2
• Concurrent tetracycline use – contraindicated due to risk of pseudotumor cerebri. (Guideline recommendation) 2

Combination Therapy with Phototherapy

• Reduce UVB dose by 30–50 % at initiation when acitretin is added, to limit UVB‑induced erythema. (Guideline recommendation) 6
• Begin with 2 weeks of acitretin monotherapy, then introduce phototherapy. (Guideline recommendation) 6
• A 25 mg daily acitretin dose combined with phototherapy can achieve efficacy comparable to 35 mg monotherapy. (Guideline recommendation) 7

Drug Interaction Alerts

• Vitamin A supplements – increase risk of hypervitaminosis A. (Guideline recommendation) 2
• Tetracyclines – additive risk of increased intracranial pressure. (Guideline recommendation) 2
• Glyburide (glibenclamide) – acitretin may alter its glucose‑lowering effect. (Guideline recommendation) 2
• Alcohol – promotes conversion of acitretin to etretinate, extending teratogenic potential. (Guideline recommendation) 2
• Methotrexate – combined use heightens hepatotoxicity risk; use with caution. (Guideline recommendation) 2

Unique Clinical Advantage

• Acitretin is non‑immunosuppressive, allowing safe continuation during active infections, unlike many other systemic psoriasis agents. (Guideline recommendation) 5

Starting and Maintaining Acitretin Therapy for Severe Plaque Psoriasis

Initial Dosing Recommendations

• The FDA‑approved dosing range for acitretin is 10–50 mg once daily; clinical practice for severe plaque psoriasis typically begins with 25–50 mg taken with the main meal to optimize absorption. [8][9]
• The American Academy of Dermatology (AAD) guidelines and the FDA label recommend initiating therapy at 25–50 mg daily for most adults with severe plaque psoriasis, balancing efficacy with tolerability. (Strong recommendation) [8][9]
• When acitretin is combined with ultraviolet (UV) therapy, a lower dose of ≤25 mg daily is advised to minimize mucocutaneous adverse effects. (Moderate recommendation) [8][9]

Dose Adjustments and Maintenance

• After achieving an initial clinical response, maintenance dosing of 25–50 mg daily is generally sufficient for continued disease control. (Strong recommendation) [8][9]
• Long‑term therapy (6–12 months) allows 75–88 % of patients with chronic plaque psoriasis to maintain at least a 50 % reduction in PASI score (PASI 50). (Moderate‑quality evidence) 10

Combination with Phototherapy

• When acitretin is added to phototherapy, the UVB dose should be reduced by 30–50 % at treatment initiation to lower the risk of erythema. (Strong recommendation) [8][9]
• Combining acitretin with phototherapy shortens the time to clearance and reduces the total cumulative radiation exposure compared with phototherapy alone. (Moderate‑quality evidence) 10

Safety Monitoring

Baseline Assessments (before starting acitretin)

• Perform a comprehensive history and physical examination.
• Obtain fasting lipid profile, complete blood count (CBC), liver function tests (LFTs), renal function tests (creatinine/eGFR), and a pregnancy test in all women of child‑bearing potential. (Strong recommendation) [8][9]

Ongoing Laboratory Monitoring

• First 8 weeks: repeat LFTs and lipid profile every 2 weeks.
• After 8 weeks: monitor LFTs and lipid profile every 6–12 weeks (or approximately every 3 months per newer guidance). (Strong recommendation) [8][9]
• CBC and renal function should be checked every 3 months. (Strong recommendation) [8][9]

Contraindications and Drug Interactions

• Absolute contraindications: pregnancy (acitretin is a potent teratogen), severely impaired hepatic or renal function, chronically elevated blood lipids, and concurrent tetracycline use (risk of pseudotumor cerebri). (Strong recommendation) [8][9]
• Drug interaction warnings: avoid co‑administration with methotrexate because of additive hepatotoxicity, and avoid vitamin A supplements due to risk of hypervitaminosis A. (Strong recommendation) [8][9]

Expected Therapeutic Timeline

• Meaningful improvement in plaque psoriasis typically requires 2–3 months of continuous acitretin therapy; rapid responses seen in pustular psoriasis (≈3 weeks) should not be expected for plaque disease. (Moderate‑quality evidence) 10